DrugPatentWatch Database Preview
PROMACTA KIT Drug Profile
When do Promacta Kit patents expire, and what generic alternatives are available?
Promacta Kit is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are eight patents protecting this drug.
This drug has one hundred and thirty-four patent family members in thirty countries.
The generic ingredient in PROMACTA KIT is eltrombopag olamine. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eltrombopag olamine profile page.
Summary for PROMACTA KIT
| International Patents: | 134 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 27 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | PROMACTA KIT at DailyMed |
Recent Clinical Trials for PROMACTA KIT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Shenzhen Second People's Hospital | Phase 3 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 4 |
| Wei Zhao | Phase 4 |
US Patents and Regulatory Information for PROMACTA KIT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | PROMACTA KIT | eltrombopag olamine | FOR SUSPENSION;ORAL | 207027-002 | Sep 27, 2018 | RX | Yes | No | See Pricing | See Pricing | Y | See Pricing | |||
| Novartis Pharms Corp | PROMACTA KIT | eltrombopag olamine | FOR SUSPENSION;ORAL | 207027-002 | Sep 27, 2018 | RX | Yes | No | See Pricing | See Pricing | Y | See Pricing | |||
| Novartis Pharms Corp | PROMACTA KIT | eltrombopag olamine | FOR SUSPENSION;ORAL | 207027-002 | Sep 27, 2018 | RX | Yes | No | See Pricing | See Pricing | Y | See Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PROMACTA KIT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | PROMACTA KIT | eltrombopag olamine | FOR SUSPENSION;ORAL | 207027-001 | Aug 24, 2015 | See Pricing | See Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PROMACTA KIT
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 372440 | See Pricing |
| Canada | 2308317 | See Pricing |
| South Korea | 100847172 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PROMACTA KIT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1534390 | C20100006 00032 | Estonia | See Pricing | PRODUCT NAME: REVOLADE-ELTROMBOPAG; REG NO/DATE: C(2010)1662 11.03.2010 |
| 1294378 | 122010000037 | Germany | See Pricing | PRODUCT NAME: ELTROMBOPAG SOWIE PHARMAZEUTISCH ANNEHMBARE SALZE, HYDRATE UND SOLVATE DAVON; NAT. REGISTRATION NO/DATE: EU/1/10/612/001-006 20100311; FIRST REGISTRATION: EU EU/1/10/612/001-/006 20100311 |
| 1534390 | 91 3-2010 | Slovakia | See Pricing | FORMER OWNER: GLAXO GROUP LIMITED, BRENTFORD, MIDDLESEX, GB; DATUM ZAPISU DO REGISTRA: 20161202 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
